5 Top Gainers In Pharma Sector (BCRX, NOVN, TOCA...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Obalon Therapeutics, Inc. (OBLN)

Obalon is medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity.

Gained 39.82% to close Thursday's (May 30) trading at $1.58.

News: No news

Recent event:

On May 23, 2019, the Company entered into definitive agreements with investors for the purchase and sale of 5 million shares of common stock, par value $0.001 per share, at an offering price of $0.60 per share, pursuant to a registered direct offering. The gross proceeds of the offering are expected to be approximately $3 million.

2. MiMedx Group, Inc. (MDXG.OB)

Gained 35.59% to close Thursday's trading at $4.51.

News: The Company's board of directors has adopted a comprehensive plan to refresh the composition of the Board.

The plan was developed by the Board in cooperation with one of the Company's largest shareholders, Prescience Point Capital Management LLC, and follows the completion of the Audit Committee's independent investigation into alleged wrongdoing by the prior senior management team.

The Company's common stock was delisted from The Nasdaq Capital Market on November 8, 2018.

3. Tocagen Inc. (TOCA)

Gained 21.33% to close Thursday's trading at $5.12.

News: No news

Pipeline:

A phase III clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma, dubbed Toca 5, is ongoing.

4. Novan Inc. (NOVN)

Gained 15.54% to close Thursday's trading at $2.23.

News: No news

Clinical Trials & Near-term Catalyst:

The Company's lead asset is SB206, a phase III-ready compound for the treatment of molluscum contagiosum.

The phase III molluscum program is getting ready to begin recruiting patients, with top-line results targeted early during the first quarter of 2020 or before.

5. BioCryst Pharmaceuticals, Inc. (BCRX)

Gained 15.46% to close Thursday's trading at $3.36.

News: Millennium Management, a capital management firm, has acquired a 5.6% stake in BioCryst.

Near-term Catalyst:

-- Filing of NDA for BCX7353 for the prevention of hereditary angioedema (HAE) attacks is expected in Q4, 2019.